BRITISH BIOTECH IND FOR STEM CELL PROTECTOR BB-10010 APPROVED
Executive Summary
BRITISH BIOTECH IND FOR STEM CELL PROTECTOR BB-10010 APPROVED Nov. 30, Chief Financial Officer James Noble told the annual Robertson, Stephens medical conference in New York City Dec. 1. "We'll be putting forward clinical trials at Indiana [University Medical Center] very shortly, I hope in the next couple of weeks," Noble continued. BB-10010 is a "genetically engineered variant" of "a natural stem cell protector in bone marrow," LD78, Noble said. British Biotechnology is pursuing "two different clinical programs" for the compound: stem cell protection and stem cell mobilization.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth